The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (114.81) USD. With the latest stock price at 67.38 USD, the upside of Nektar Therapeutics based on DCF is -270.4%.
Based on the latest price of 67.38 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 270.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 8.7% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (345.50) - (71.15) | (114.81) |
| Upside | -612.8% - -205.6% | -270.4% |